Demographic characteristics by conditioning regimen among patients with myeloid malignancies who received HCT with myeloablative conditioning from 2009 to 2011
| Characteristics of patients . | IV-BU . | TBI . |
|---|---|---|
| N = 1025 (%) . | N = 458 (%) . | |
| Number of centers | 104 | 79 |
| Geographic region | ||
| North America | 1020 (99) | 444 (97) |
| South America | 5 (<1) | 14 (3) |
| Age, median (range), years | 46 (<1-60) | 43 (1-60) |
| Gender | ||
| Male | 510 (50) | 238 (52) |
| Patient ethnicity | ||
| White | 906 (88) | 404 (88) |
| African American | 54 (5) | 19 (4) |
| Asian | 29 (3) | 12 (3) |
| Other | 36 (4) | 23 (5) |
| Performance score | ||
| Karnofsky: 90%-100% | 598 (66) | 277 (65) |
| Lansky: 90%-100% | 106 (91) | 29 (88) |
| HCI-CI | ||
| 0 | 400 (39) | 209 (46) |
| 1-2 | 302 (29) | 112 (24) |
| ≥3 | 323 (32) | 137 (30) |
| Disease and disease status | ||
| AML early | 415 (40) | 182 (40) |
| AML intermediate | 143 (14) | 82 (18) |
| AML advanced | 143 (14) | 95 (21) |
| CML early | 59 (6) | 24 (5) |
| CML intermediate | 21 (2) | 24 (5) |
| CML advanced | 28 (3) | 6 (1) |
| MDS early | 62 (6) | 11 (2) |
| MDS advanced | 151 (15) | 33 (7) |
| MDS NOS | 3 (<1) | 1 (<1) |
| Prior autologous transplant | 21 (2) | 11 (2) |
| Graft type | ||
| Bone marrow | 238 (23) | 110 (24) |
| Peripheral blood | 787 (77) | 348 (76) |
| Donor type | ||
| HLA-identical sibling | 417 (41) | 180 (39) |
| Well-matched unrelated | 479 (47) | 231 (50) |
| Partially matched unrelated | 115 (11) | 43 (9) |
| Mismatched | 2 (<1) | 2 (<1) |
| HLA match information missing unrelated | 12 (1) | 2 (<1) |
| D-R sex match | ||
| F-M | 194 (19) | 91 (20) |
| F-F | 204 (20) | 88 (19) |
| M-M | 316 (31) | 147 (32) |
| M-F | 311 (30) | 132 (29) |
| D-R CMV status | ||
| −/− | 301 (29) | 136 (30) |
| +/+ | 267 (26) | 117 (26) |
| +/− | 135 (13) | 58 (13) |
| −/+ | 321 (31) | 146 (32) |
| Missing | 1 (<1) | 1 (<1) |
| Conditioning regimen | ||
| FLU + BU | 289 (28) | 0 |
| FLU + BU + ATG/Campath | 135 (13) | 0 |
| BU + CY +/− others | 500 (49) | 0 |
| BU + CY +/− OTHERS + ATG/Campath | 101 (10) | 0 |
| CY + TBI +/− others | 0 | 396 (86) |
| CY + TBI +/− others + ATG/Campath | 0 | 47 (10) |
| Etoposide + TBI (No Cy) | 0 | 15 (3) |
| Total BU dose for patients who received IV BU, median (range), mg/kg | 13 (10-28) | — |
| BU schedule | — | |
| Every 6 h | 586 (57) | — |
| Daily | 427 (42) | — |
| Twice daily | 7 (<1) | — |
| Other schedule | 5 (<1) | — |
| PKs vs non-PKs | — | |
| No | 447 (44) | — |
| Yes | 578 (56) | — |
| BU dose-adjusted based on PK with a plan | — | |
| No | 122 (22) | — |
| Yes | 443 (78) | — |
| Fractionated TBI | ||
| No | — | 21 (5) |
| Yes | — | 437 (95) |
| TBI dose median (range) cGy | ||
| Unfractionated | — | 550 (550-900) |
| Fractionated | — | 1200 (990-1440) |
| BU dose if no PK, median (range), mg/kg* | 13 (10-17) | — |
| BU dose if PK, median (range), mg/kg† | 14 (10-27) | |
| GVHD prophylaxis | ||
| Tacro+MTX+/− other | 645 (63) | 322 (70) |
| Tacro+MMF+/− other | 133 (13) | 20 (4) |
| CSA+MTX+/− other | 146 (14) | 74 (16) |
| CSA+MMF+/− other | 30 (3) | 9 (2) |
| CSA or Tacro +/− other | 71 (7) | 33 (7) |
| ATG/Campath | ||
| CNI-based +ATG/Campath | 297 (29) | 65 (14) |
| Median follow-up of survivors, range, months | 22 (3-36) | 23 (8-37) |
| Characteristics of patients . | IV-BU . | TBI . |
|---|---|---|
| N = 1025 (%) . | N = 458 (%) . | |
| Number of centers | 104 | 79 |
| Geographic region | ||
| North America | 1020 (99) | 444 (97) |
| South America | 5 (<1) | 14 (3) |
| Age, median (range), years | 46 (<1-60) | 43 (1-60) |
| Gender | ||
| Male | 510 (50) | 238 (52) |
| Patient ethnicity | ||
| White | 906 (88) | 404 (88) |
| African American | 54 (5) | 19 (4) |
| Asian | 29 (3) | 12 (3) |
| Other | 36 (4) | 23 (5) |
| Performance score | ||
| Karnofsky: 90%-100% | 598 (66) | 277 (65) |
| Lansky: 90%-100% | 106 (91) | 29 (88) |
| HCI-CI | ||
| 0 | 400 (39) | 209 (46) |
| 1-2 | 302 (29) | 112 (24) |
| ≥3 | 323 (32) | 137 (30) |
| Disease and disease status | ||
| AML early | 415 (40) | 182 (40) |
| AML intermediate | 143 (14) | 82 (18) |
| AML advanced | 143 (14) | 95 (21) |
| CML early | 59 (6) | 24 (5) |
| CML intermediate | 21 (2) | 24 (5) |
| CML advanced | 28 (3) | 6 (1) |
| MDS early | 62 (6) | 11 (2) |
| MDS advanced | 151 (15) | 33 (7) |
| MDS NOS | 3 (<1) | 1 (<1) |
| Prior autologous transplant | 21 (2) | 11 (2) |
| Graft type | ||
| Bone marrow | 238 (23) | 110 (24) |
| Peripheral blood | 787 (77) | 348 (76) |
| Donor type | ||
| HLA-identical sibling | 417 (41) | 180 (39) |
| Well-matched unrelated | 479 (47) | 231 (50) |
| Partially matched unrelated | 115 (11) | 43 (9) |
| Mismatched | 2 (<1) | 2 (<1) |
| HLA match information missing unrelated | 12 (1) | 2 (<1) |
| D-R sex match | ||
| F-M | 194 (19) | 91 (20) |
| F-F | 204 (20) | 88 (19) |
| M-M | 316 (31) | 147 (32) |
| M-F | 311 (30) | 132 (29) |
| D-R CMV status | ||
| −/− | 301 (29) | 136 (30) |
| +/+ | 267 (26) | 117 (26) |
| +/− | 135 (13) | 58 (13) |
| −/+ | 321 (31) | 146 (32) |
| Missing | 1 (<1) | 1 (<1) |
| Conditioning regimen | ||
| FLU + BU | 289 (28) | 0 |
| FLU + BU + ATG/Campath | 135 (13) | 0 |
| BU + CY +/− others | 500 (49) | 0 |
| BU + CY +/− OTHERS + ATG/Campath | 101 (10) | 0 |
| CY + TBI +/− others | 0 | 396 (86) |
| CY + TBI +/− others + ATG/Campath | 0 | 47 (10) |
| Etoposide + TBI (No Cy) | 0 | 15 (3) |
| Total BU dose for patients who received IV BU, median (range), mg/kg | 13 (10-28) | — |
| BU schedule | — | |
| Every 6 h | 586 (57) | — |
| Daily | 427 (42) | — |
| Twice daily | 7 (<1) | — |
| Other schedule | 5 (<1) | — |
| PKs vs non-PKs | — | |
| No | 447 (44) | — |
| Yes | 578 (56) | — |
| BU dose-adjusted based on PK with a plan | — | |
| No | 122 (22) | — |
| Yes | 443 (78) | — |
| Fractionated TBI | ||
| No | — | 21 (5) |
| Yes | — | 437 (95) |
| TBI dose median (range) cGy | ||
| Unfractionated | — | 550 (550-900) |
| Fractionated | — | 1200 (990-1440) |
| BU dose if no PK, median (range), mg/kg* | 13 (10-17) | — |
| BU dose if PK, median (range), mg/kg† | 14 (10-27) | |
| GVHD prophylaxis | ||
| Tacro+MTX+/− other | 645 (63) | 322 (70) |
| Tacro+MMF+/− other | 133 (13) | 20 (4) |
| CSA+MTX+/− other | 146 (14) | 74 (16) |
| CSA+MMF+/− other | 30 (3) | 9 (2) |
| CSA or Tacro +/− other | 71 (7) | 33 (7) |
| ATG/Campath | ||
| CNI-based +ATG/Campath | 297 (29) | 65 (14) |
| Median follow-up of survivors, range, months | 22 (3-36) | 23 (8-37) |